Design of population pharmacokinetic experiments using prior information

Xenobiotica

Volumn 37, Issue 10-11, 2007, Pages 1311-1330

  Ogungbenro, K ^a   Aarons, L ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

D optimality; Fisher information matrix; Mixed effects; Optimal design; Population pharmacokinetics; Simulation

Indexed keywords

ALGORITHM; BAYES THEOREM; CALCULATION; COMPUTER PROGRAM; EXPERIMENT; INFORMATION; METHODOLOGY; PHARMACOKINETICS; POPULATION RESEARCH; REVIEW; SAMPLE SIZE; SAMPLING; SIMULATION; STOCHASTIC MODEL;

ALGORITHMS; ANIMALS; BAYES THEOREM; DRUG DESIGN; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; SOFTWARE; XENOBIOTICS;

EID: 35648935076     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250701553315     Document Type: Review

References (77)

1. Aarons L. 1991. Population pharmacokinetics: Theory and practice. British Journal of Clinical Pharmacology 32:669-670.
2. Aarons L. 1992. Population pharmacokinetics. International Journal of Clinical Pharmacology. Therapeutics and Toxicology 30:520-522.
3. Aarons L. 1999. Software for population pharmacokinetics and pharmacodynamics. Clinical Pharmacokinetics 36:255-264.
4. Aarons L, Balant LP, Mentré F, Morselli PL, Rowland M, Steimer JL, Vozeh S. 1996. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. European Journal of Clinical Pharmacology 49:251-254.
5. Al Banna MK, Kelman AW, Whiting B. 1990. Experimental design and efficient parameter estimation in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 18:347-360.
6. Atkinson AC, Chaloner K, Herzberg AM, Juritz J. 1993. Optimum experimental designs for properties of a compartmental model. Biometrics 49:325-337.
7. Atkinson AC, Donev AN. 1992. Optimum experimental designs. Oxford: Oxford University Press.
8. Atkinson AC, Haines LM. 1996. Designs for nonlinear and generalized linear models. In: Ghosh S, Rao CR, editors. Handbook of statistics 13. Amsterdam: Elsevier Science. pp 437-476.
9. Bogacka B, Patan M. 2006. Efficient sampling windows for parameter estimation in population models. Population Approach Group Europe (PAGE). 15: Abstr 963.
10. Chaloner K, Larntz K. 1989. Optimal Bayesian design applied to logistic regression experiments. Journal of Statistical Planning and Inference 21:191-208.
11. Chenel M, Ogungbenro K, Duval V, Laveille C, Jochemsen R, Aarons L. 2005. Optimal blood sampling time windows for parameter estimation using a population approach: Design of a phase II clinical trial. Journal of Pharmacokinetics and Pharmacodynamics 32:737-756.
12. Colburn WA, Lee JW. 2003. Biomarkers, validation and pharmacokinetic- pharmacodynamic modelling. Clinical Pharmacokinetics 42:997-1022.
13. Cooper L, Steinberg D. 1970. Introduction to methods of optimisation. Philadelphia, PA: W. B. Saunders.
14. Corana A, Marchesi M, Martini C, Ridella S. 1987. Minimizing multimodal functions of continuous variables with the 'simulated annealing' algorithm. ACM Transactions on Mathematical Software 13:262-280.
15. d'Argenio DZ. 1981. Optimal sampling times for pharmacokinetic experiments. Journal of Pharmacokinetics and Biopharmaceutics 9:739-756.
16. d'Argenio DZ. 1990. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments. Mathematical Biosciences 99:105-118.
17. Dufull S, Ecdeston JA, Kimko HC, Denman N. 2006. WinPOPT: Optimization for population PKPD study design. http://www.winpopt.com.
18. Duffull SB, Mentré F, Aarons L. 2001. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharmaceutical Research 18:83-89.
19. Duffull SB, Retout S, Mentré F. 2002. The use of simulated annealing for finding optimal population designs. Computer Methods and Programs in Biomedicine 69:25-35.
20. Endrenyi L. 1981. Design of experiments for estimating enzyme and pharmacokinetic parameters in kinetic data analysis. In: Endrenyi L, editor. Design and analysis of enzyme and pharmacokinetic experiments. New York, NY: Plenum. pp 121-167.
21. Endrenyi L, Chan FY. 1981. Optimal design of experiments for the estimation of precise hyperbolic kinetic and binding parameters. Journal of Theoretical Biology 90:241-263.
22. Fedorov VV. 1972. Theory of experiments. New York, NY: Academic Press.
23. Fedorov VV, Hackl P. 1997. Model-oriented design of experiments. New York, NY: Springer.
24. Foracchia M, Hooker A, Vicini P, Ruggeri A. 2004. POPED, a software for optimal experiment design in population kinetics. Computer Methods and Programs in Biomedicine 74:29-46.
25. Gagnon R, Leonov S. 2005. Optimal population designs for PK models with serial sampling. Journal of Biopharmaceutical Statistics 15:143-163.
26. Goffe WL, Ferrier GD, Rogers J. 1994. Global optimization of statistical functions with simulated annealing. Journal of Econometrics 60:65-99.
27. Graham G, Aarons J. 2004. Optimal blood sampling time windows for parameter estimation in individual and population pharmacokinetic experiments. Statistics in Medicine 25:4004-4019.
28. Green B, Duffull SB. 2003a. Development of a dosing strategy for enoxaparin in obese patients. British Journal of Clinical Pharmacology 56:96-103.
29. Green B, Duffull SB. 2003b. Prospective evaluation of a D-optimal designed population pharmacokinetic study. Journal of Pharmacokinetics and Pharmacodynamics 30:145-161.
30. Gueorguieva I, Aarons L, Ogungbenro K, Jorga KM, Rodgers T, Rowland M. 2006. Optimal design for multivariate response pharmacokinetic models. Journal of Pharmacokinetics and Pharmacodynamics 33:97-124.
31. Gueorguieva I, Ogungbenro K, Graham G, Glatt S, Aarons L. 2007. A program for individual and population optimal design for univariate and multivariate response pharmacokinetic-pharmacodynamic models. Computer Methods and Programs in Biomedicine 86:51-61.
32. Haines LM. 1987. The application of the annealing algorithm to the construction of exact optimal designs for linear-regression models. Technometrics 29:439-447.
33. Hale M, Gillespie WR, Gupta SK, Tuk B, Holford NH. 1996. Clinical trial simulation, streamlining your drug development process. Applied Clinical Trials 5:35-40.
34. Hashimoto Y, Sheiner LB. 1991. Designs for population pharmacodynamics: Value of pharmacokinetic data and population analysis. Journal of Pharmacokinetics and Biopharmaceutics 19:333-353.
35. Hennig S, Waterhouse TH, Bell SC, France M, Wainwright CE, Miller H, Charles BG, Duffull SB. 2007. A d-optimal designed population pharmacokinetic study of oral itraconazole in adult cystic fibrosis patients. British Journal of Clinical Pharmacology 63:438-450.
36. Holford NH, Sheiner LB. 1982. Kinetics of pharmacologic response. Pharmacology and Therapeutics 16:143-166.
37. Jonsson EN, Wade JR, Karlsson MO. 1996. Comparison of some practical sampling strategies for population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 24:245-263.
38. Kang D, Schwartz JB, Verotta D. 2004. A sample size computation method for non-linear mixed effects models with applications to pharmacokinetic models. Statistics in Medicine 23:2551-2566.
39. Kang D, Schwartz JB, Verotta D. 2005. Sample size computations for PK/PD population models. Journal of Pharmacokinetics and Pharmacodynamics 32:685-701.
40. Kowalski KG, Hutmacher MM. 2001. Design evaluation for a population pharmacokinetic study using clinical trial simulations: A case study. Statistics in Medicine 20:75-91.
41. Lagarias JC, Reeds JA, Wright MH, Wright PE. 1998. Convergence of the Nelder-Mead simplex method in low dimensions. SIAM Journal of Optimisation 9:112-147.
42. Lee PI. 2001. Design and power of a population pharmacokinetic study. Pharmaceutical Research 18:75-82.
43. Masri SF, Bekey GA. 1980. A global optimisation algorithm using adaptive random search. Applied Mathematics and Computing 7:353-375.
44. McKinnon KIM. 1998. Convergence of the Nelder-Mead simplex method to a nonstationary point. SIAM Journal of Optimisation 9:148-158.
45. Mentré F, Mallet A, Baccar D. 1997. Optimal design in random-effects regression models. Biometrika 84:429-442.
46. Merle Y, Mentré F. 1995. Bayesian design criteria: Computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model. Journal of Pharmacokinetics and Biopharmaceutics 23:101-125.
47. Montgomery DC. 2001. Design and analysis of experiments. 5th ed. New York, NY: Wiley.
48. Nelder JA, Mead R. 1965. A simplex method for function minimization. Computer Journal 7:308-313.
49. Ogungbenro K, Aarons L. 2003. Sample size calculation based on confidence interval for pharmacokinetic experiments. Population Approach Group Europe (PAGE). 12: Abstr 404.
50. Ogungbenro K, Aarons L, Graham G. 2006. Sample size calculations based on generalized estimating equations for population pharmacokinetic experiments. Journal of Biopharmaceutical Statistics 16:135-150.
51. Ogungbenro K, Graham G, Gueorguieva I, Aarons L. 2005. The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments. Computer Methods and Programs in Biomedicine 80:115-125.
52. Ogungbenro K, Gueorguieva I, Majid O, Graham G, Aarons L. 2007. Optimal design for multiresponse pharmacokinetic-pharmacodynamic models: Dealing with unbalanced designs. Journal of Pharmacokinetics and Pharmacodynamics Accepted 05-07-2007.
53. Press WH, Flannery BP, Teukolsky SA, Vettering WT. 1988. Numerical recipes in C. Cambridge: Cambridge University Press.
54. Pronzato L. 2002. Information matrices with random regressors. Application to experimental designs. Journal of Statistical Planning and Inference 108:189-200.
55. Pronzato L, Walter E. 1985. Robust experiment design via stochastic approximation. Mathematical Biosciences 75:103-120.
56. Pronzato L, Walter E, Venot A, Lebruchec JF. 1984. A general-purpose global optimizer: Implementation and applications. Mathematics and Computers in Simulation 26:412-422.
57. PWC. 2005. PriceWaterhouseCoopers Pharma 2005, an industrial revolution in R&D (available at: http://www.pwc.com/gx/eng/about/ind/pharma/ industrial_revolution.pdf)
58. Retout S, Comets E, Nagard HL, Mentré F. 2006. New features for population design evaluation and optimisation in R:PFIM 2.0 and PFIMOPT 2.0. Population Approach Group Europe (PAGE). 15: Abstr 1006.
59. Retout S, Duffull S, Mentré F. 2001. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Computer Methods and Programs in Biomedicine 65:141-151.
60. Retout S, Mentré F. 2003a. Further developments of the Fisher information matrix in nonlinear mixed effects models with evaluation in population pharmacokinetics. Journal of Biopharmaceutical Statistics 13:209-227.
61. Retout S, Mentré F. 2003b. Optimization of individual and population designs using Splus. Journal of Pharmacokinetics and Pharmacodynamics 30:417-443.
62. Retout S, Mentré F, Bruno R. 2002. Fisher information matrix for non-linear mixed-effects models: Evaluation and application for optimal design of enoxaparin population pharmacokinetics. Statistics in Medicine 21:2623-2639.
63. Ribbing J, Jonsson EN. 2004. Power, selection bias and predictive performance of the population pharmacokinetic covariate model. Journal of Pharmacokinetics and Pharmacodynamics 31:109-134.
64. Rowland M, Tozer T. 2005. Clinical pharmacokinetics, concepts and applications. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins.
65. Sheiner LB, Rosenberg B, Marathe VV. 1977. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics 5:445-479.
66. Tod M, Mentré F, Merle Y, Mallet A. 1998. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 26:689-716.
67. Tod M, Rocchisani JM. 1996. Implementation of OSPOP, an algorithm for the estimation of optimal sampling times in pharmacokinetics by the ED, EID and API criteria. Computer Methods and Programs in Biomedicine 50:13-22.
68. Tod M, Rocchisani JM. 1997. Comparison of ED, EID, and API criteria for the robust optimization of sampling times in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 25:515-537.
69. Vozeh S, Steimer JL, Rowland M, Morselli P, Mentré F, Balant LP, Aarons L. 1996. The use of population pharmacokinetics in drug development. Clinical Pharmacokinetics 30:81-93.
70. Walter E, Pronzato L. 1987. Optimal experiment design for nonlinear models subject to large prior uncertainties. American Journal of Physiology 253:R530-R534.
71. Walter E, Pronzato L. 1997. Identification of parametric models from experimental data. London: Springer.
72. Wang J, Endrenyi L. 1992. A computationally efficient approach for the design of population pharmacokinetic studies. Journal of Pharmacokinetics and Biopharmaceutics 20:279-294.
73. Waterhouse TH, Redmann S, Duffull SB, Eccleston JA. 2005. Optimal design for model discrimination and parameter estimation for itraconazole population pharmacokinetics in cystic fibrosis patients. Journal of Pharmacokinetics and Pharmacodynamics 32:521-545.
74. White DB, Walawander CA, Liu DY, Grasela TH. 1992. Evaluation of hypothesis testing for comparing two populations using NONMEM analysis. Journal of Pharmacokinetics and Biopharmaceutics 20:295-313.
75. WinPOPT: Optimization for population PKPD study design 2006.
76. Wynn PH. 1970. The sequential generation of D-optimum experimental designs. Annals of Mathematical Statistics 41:1655-1664.
77. Yuh L, Beal S, Davidian M, Harrison F, Hester A, Kowalski K, Vonesh E, Wolfinger R. 1994. Population pharmacokinetic/pharmacodynamic methodology and applications: A bibliography. Biometrics 50:566-575.